Mechanisms of genetic variation in polioviruses

Reviews in Medical Virology

Volumn 20, Issue 6, 2010, Pages 358-371

  Savolainen Kopra, Carita ^a   Blomqvist, Soile ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; POLIOMYELITIS VACCINE; PROTEIN VP1; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DISEASE TRANSMISSION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; MICROBIAL DIVERSITY; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; REVIEW; RNA SEQUENCE; VIRUS CAPSID; VIRUS MUTATION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN;

ADAPTATION, BIOLOGICAL; BIOLOGICAL EVOLUTION; EVOLUTION, MOLECULAR; GENETIC VARIATION; HUMANS; MUTATION; POLIOVIRUS; RECOMBINATION, GENETIC;

EID: 77958523914     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.663     Document Type: Review

References (119)

1. Salk D. Herd effect and virus eradication with use of killed poliovirus vaccine. Dev Biol Stand 1981; 47: 247-255.
2. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973; 1: 115-118.
3. WHO. Global eradication of poliomyelitis by the year 2000. Resolution WHA41.28.
4. WHO. Wild Poliovirus Weekly Update. [Accessed on 18th January 2010], 2010.
5. Racaniello VR. Picornaviridae: the viruses and their replication. In Fields Virology, 5th edn, Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins, a Wolters Kluwer Business: Philadelphia, 2007; 795-838.
6. Knowles NJ. Polioviruses are members of HEV-C. 2008.
7. Jiang P, Faase JA, Toyoda H, et al. Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. Proc Natl Acad Sci USA 2007; 104: 9457-9462.
8. Jarvis TC, Kirkegaard K. Poliovirus RNA recombination: mechanistic studies in the absence of selection. EMBO J 1992; 11: 3135-3145.
9. Drake JW. A constant rate of spontaneous mutation in DNA-based microbes. Proc Natl Acad Sci USA 1991; 88: 7160-7164.
10. Friedberg EC, Walker GC, Siede W. DNA Repair and Mutagenesis. American Society of Microbiology: Washington DC; 1995.
11. Freistadt MS, Vaccaro JA, Eberle KE. Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol J 2007; 4: 44.
12. Domingo E, Escarmis C, Sevilla N, et al. Basic concepts in RNA virus evolution. FASEB J 1996; 10: 859-864.
13. Domingo E, Sabo D, Taniguchi T, et al. Nucleotide sequence heterogeneity of an RNA phage population. Cell 1978; 13: 735-744.
14. Muller HJ. The relation of recombination to mutational advance. Mutat Res 1964; 106: 2-9.
15. Gavrilin GV, Cherkasova EA, Lipskaya GY, et al. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J Virol 2000; 74: 7381-7390.
16. Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. Molecular epidemiology of polioviruses. Semin Virol 1995; 6: 401-414.
17. Liu HM, Zheng DP, Zhang LB, et al. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol 2000; 74: 11153-11161.
18. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998; 36: 2893-2899.
19. Oberste MS, Williamson JC, Greenwood JD, et al. Characterization of bovine immunodeficiency virus rev cDNAs and identification and subcellular localization of the Rev protein. J Virol 1993; 67: 6395-6405.
20. Yang CF, Chen HY, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 2005; 79: 12623-12634.
21. Martin J, Dunn G, Hull R, et al. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J Virol 2000; 74: 3001-3010.
22. Jorba J, Campagnoli R, De L, et al. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 2008; 82: 4429-4440.
23. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296: 356-359.
24. Crotty S, Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect 2002; 4: 1301-1307.
25. Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu Rev Genet 1993; 27: 353-436.
26. Mateu MG, Hernandez J, Martinez MA, et al. Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites. J Virol 1994; 68: 1407-1417.
27. Hirst GK. Genetic recombination with Newcastle disease virus, polioviruses, and influenza. Cold Spring Harb Symp Quant Biol 1962; 27: 303-309.
28. Ledinko N. Genetic recombination with poliovirus type 1. Studies of crosses between a normal horse serum-resistant mutant and several guanidine-resistant mutants of the same strain. Virology 1963; 20: 107-119.
29. Copper PD, Steiner-Pryor A, Scotti PD, et al. On the nature of poliovirus genetic recombinants. J Gen Virol 1974; 23: 41-49.
30. Lai MM. RNA recombination in animal and plant viruses. Microbiol Rev 1992; 56: 61-79.
31. Duggal R, Cuconati A, Gromeier M, et al. Genetic recombination of poliovirus in a cell-free system. Proc Natl Acad Sci USA 1997; 94: 13786-13791.
32. Kirkegaard K, Baltimore D. The mechanism of RNA recombination in poliovirus. Cell 1986; 47: 433-443.
33. Nagy PD, Bujarski JJ. Efficient system of homologous RNA recombination in brome mosaic virus: sequence and structure requirements and accuracy of crossovers. J Virol 1995; 69: 131-140.
34. Nagy PD, Zhang C, Simon AE. Dissecting RNA recombination in vitro: role of RNA sequences and the viral replicase. EMBO J 1998; 17: 2392-2403.
35. Simon AE, Nagy PD. RNA recombination in turnip crinkle virus: its role in formation of chimeric RNAs, multimers, and in 3'-end repair. Semin Virol 1996; 7: 373-379.
36. Gmyl AP, Belousov EV, Maslova SV, et al. Nonreplicative RNA recombination in poliovirus. J Virol 1999; 73: 8958-8965.
37. Gmyl AP, Korshenko SA, Belousov EV, et al. Nonreplicative homologous RNA recombination: promiscuous joining of RNA pieces? RNA 2003; 9: 1221-1231.
38. Tolskaya EA, Romanova LI, Blinov VM, et al. Studies on the recombination between RNA genomes of poliovirus: the primary structure and nonrandom distribution of crossover regions in the genomes of intertypic poliovirus recombinants. Virology 1987; 161: 54-61.
39. White KA, Morris TJ. RNA determinants of junction site selection in RNA virus recombinants and defective interfering RNAs. RNA 1995; 1: 1029-1040.
40. Pilipenko EV, Gmyl AP, Agol VI. A model for rearrangements in RNA genomes. Nucleic Acids Res 1995; 23: 1870-1875.
41. Cuervo NS, Guillot S, Romanenkova N, et al. Genomic features of intertypic recombinant sabin poliovirus strains excreted by primary vaccinees. J Virol 2001; 75: 5740-5751.
42. Gorbalenya AE. Host-related sequences in RNA viral genomes. Semin Virol 1992; 3: 359-371.
43. Koonin EV, Dolja VV. Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. Crit Rev Biochem Mol Biol 1993; 28: 375-430.
44. Agol VI. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol 2006; 299: 211-259.
45. Savolainen-Kopra C, Samoilovich E, Kahelin H, et al. Comparison of poliovirus recombinants: accumulation of point mutations provides further advantages. J Gen Virol 2009; 90: 1859-1868.
46. Worobey M, Holmes EC. Evolutionary aspects of recombination in RNA viruses. J Gen Virol 1999; 80(Pt 10): 2535-2543.
47. King AM. Preferred sites of recombination in poliovirus RNA: an analysis of 40 intertypic cross-over sequences. Nucleic Acids Res 1988; 16: 11705-11723.
48. Romanova LI, Blinov VM, Tolskaya EA, et al. The primary structure of crossover regions of intertypic poliovirus recombinants: a model of recombination between RNA genomes. Virology 1986; 155: 202-213.
49. Blomqvist S, Bruu AL, Stenvik M, et al. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1. J Gen Virol 2003; 84: 573-580.
50. Martin J, Samoilovich E, Dunn G, et al. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis. J Virol 2002; 76: 10921-10928.
51. Dedepsidis E, Pliaka V, Kyriakopoulou Z, et al. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant. FEMS Immunol Med Microbiol 2008; 52: 343-351.
52. Kyriakopoulou Z, Kottaridi C, Dedepsidis E, et al. Molecular characterization of wild-type polioviruses isolated in Greece during the 1996 outbreak in Albania. J Clin Microbiol 2006; 44: 1150-1152.
53. WHO. Transmission of wild poliovirus type 2 - Apparent global interruption., 2001.
54. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-Derived Polioviruses and the Endgame Strategy for Global Polio Eradication (*). Annu Rev Microbiol 2005; 59: 587-635.
55. Rico-Hesse R, Pallansch MA, Nottay BK, et al. Geographic distribution of wild poliovirus type 1 genotypes. Virology 1987; 160: 311-322.
56. Hovi T, Lindholm N, Savolainen C, et al. Evolution of wild-type 1 poliovirus in two healthy siblings excreting the virus over a period of 6 months. J Gen Virol 2004; 85: 369-377.
57. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151: 420-436.
58. Sabin AB. Status of field trials with an orally administered, live attenuated poliovirus vaccine. J Am Med Assoc 1959; 171: 863-868.
59. Li CP, Schaeffer M. Isolation of a non-neurotropic variant of type I poliomyelitis virus. Proc Soc Exp Biol Med 1954; 87: 148-153.
60. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand 1973; 1: 115-118.
61. Minor PD. The molecular biology of poliovaccines. J Gen Virol 1992; 73: 3065-3077.
62. Nomoto A, Omata T, Toyoda H, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci USA 1982; 79: 5793-5797.
63. Kawamura N, Kohara M, Abe S, et al. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol 1989; 63: 1302-1309.
64. Bouchard MJ, Lam DH, Racaniello VR. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J Virol 1995; 69: 4972-4978.
65. Omata T, Kohara M, Kuge S, et al. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol 1986; 58: 348-358.
66. Paul AV, Mugavero J, Yin J, et al. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 2000; 272: 72-84.
67. Macadam AJ, Pollard SR, Ferguson G, et al. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology 1991; 181: 451-458.
68. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192: 18-126.
69. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 1991; 65: 1377-1382.
70. Cann AJ, Stanway G, Hughes PJ, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 1984; 12: 7787-7792.
71. Weeks-Levy C, Tatem JM, DiMichele SJ, et al. Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology 1991; 185: 934-937.
72. Tatem JM, Weeks-Levy C, Georgiu A, et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol 1992; 66: 3194-3197.
73. Macadam AJ, Arnold C, Howlett J, et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 1989; 172: 408-414.
74. Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989; 63: 1338-1344.
75. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175 (Suppl 1): S176-S182.
76. Minor PD, Dunn G. The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. J Gen Virol 1988; 69: 1091-1096.
77. Yakovenko ML, Cherkasova EA, Rezapkin GV, et al. Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties. J Virol 2006; 80: 2641-2653.
78. Yoshida H, Horie H, Matsuura K, et al. Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 2002; 83: 1107-1111.
79. Adu F, Iber J, Bukbuk D, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res 2007; 127: 17-25.
80. Cammack N, Phillips A, Dunn G, et al. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 1988; 167: 507-514.
81. Georgescu MM, Delpeyroux F, Tardy-Panit M, et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994; 68: 8089-8101.
82. Dowdle WR, De Gourville E, Kew OM, et al. Polio eradication: the OPV paradox. Rev Med Virol 2003; 13: 277-291.
83. Nkowane BM, Wassilak SG, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 257: 1335-1340.
84. Buttinelli G, Donati V, Fiore S, et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 2003; 84: 1215-1221.
85. Cherkasova EA, Yakovenko ML, Rezapkin GV, et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 2005; 79: 1062-1070.
86. Kohler KA, Banerjee K, Gary Hlady W, et al. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ 2002; 80: 210-216.
87. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59: 587-635.
88. Lipskaya GY, Muzychenko AR, Kutitova OK, et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J Med Virol 1991; 35: 290-296.
89. Combiescu M, Guillot S, Persu A, et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch Virol 2007; 152: 727-738.
90. Cherkasova EA, Korotkova EA, Yakovenko ML, et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 2002; 76: 6791-6799.
91. Arita M, Zhu SL, Yoshida H, et al. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J Virol 2005; 79: 12650-12657.
92. Update on vaccine-derived polioviruses. MMWR Morb Mortal Wkly Rep 2006; 55: 1093-1097.
93. Laboratory surveillance for wild and vaccine-derived polioviruses-worldwide, January 2006-June 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 965-969.
94. Laboratory surveillance for wild and vaccine-derived polioviruses-worldwide, January 2007-June 2008. MMWR Morb Mortal Wkly Rep 2008; 57: 967-970.
95. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 1002-1006.
96. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003; 77: 8366-8377.
97. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 2004; 78: 13512-13521.
98. Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis 2006; 194: 545-551.
99. Estivariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis 2008; 197: 347-354.
100. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003; 9: 885-887.
101. Riquet FB, Blanchard C, Jegouic S, et al. Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus. J Virol 2008; 82: 8927-8932.
102. Jegouic S, Joffret ML, Blanchard C, et al. Recombination between polioviruses and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived polioviruses. PLoS Pathog 2009; 5: e1000412.
103. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199: 391-397.
104. Rakoto-Andrianarivelo M, Guillot S, Iber J, et al. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog 2007; 3: e191.
105. Bellmunt A, May G, Zell R, et al. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 1999; 265: 178-184.
106. Halsey NA, Pinto J, Espinosa-Rosales F, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 2004; 82: 3-8.
107. Khetsuriani N, Prevots DR, Quick L, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 2003; 188: 1845-1852.
108. MacLennan C, Dunn G, Huissoon AP, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 2004; 363: 1509-1513.
109. Minor P. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev Biol 2001; 105: 75-80.
110. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006; 34: 117-122.
111. Avellon A, Cabrerizo M, de Miguel T, et al. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerg Infect Dis 2008; 14: 1807-1809.
112. Odoom JK, Yunus Z, Dunn G, et al. Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient. J Virol 2008; 82: 9179-9190.
113. Blomqvist S, Savolainen C, Laine P, et al. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J Virol 2004; 78: 4876-4883.
114. Cernakova B, Sobotova Z, Rovny I, et al. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur J Clin Microbiol Infect Dis 2005; 24: 438-439.
115. Shulman LM, Manor Y, Handsher R, et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J Clin Microbiol 2000; 38: 3729-3734.
116. van der Sanden S, Pallansch MA, van de Kassteele J, et al. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol 2009; 83: 8693-8704.
117. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003; 77: 8366-8377.
118. Tamura K, Dudley J, Nei M, et al. MEG A4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-1599.
119. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. Proc Natl Acad Sci USA 2004; 101: 11030-11035.